Tumor Necrosis Factor-α Inhibitor Use Is Not Associated with Lipid Changes in Rheumatoid Arthritis

被引：4
|
作者：
Bili, Androniki [1 ]
Morris, Stephanie J. [1 ]
Sartorius, Jennifer A. [1 ]
Kirchner, H. Les [1 ]
Antohe, Jana L. [1 ]
Dancea, Sorina [1 ]
Wasko, Mary Chester [1 ]
机构：
[1] Geisinger Hlth Syst, Dept Rheumatol, Danville, PA 17822 USA
来源：
JOURNAL OF RHEUMATOLOGY | 2012年 / 39卷 / 05期
关键词：
RHEUMATOID ARTHRITIS; LIPIDS; TUMOR NECROSIS FACTOR-alpha INHIBITORS; INFLIXIMAB TREATMENT; INSULIN-RESISTANCE; PROFILE; THERAPY; PATTERNS;
D O I：
10.3899/jrheum.111093
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Objective. To determine the association of use of tumor necrosis factor-alpha (TNF-alpha) inhibitors with differences in lipid levels in patients with rheumatoid arthritis (RA). Methods. We studied 807 patients with incident RA to compare differences in lipid levels in TNF-alpha inhibitor users versus nonusers, with adjustment for relevant covariables. Results. TNF-alpha inhibitor use was not associated with differences in levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC), triglycerides, LDL:HDL, or TC:HDL compared to nonusers. Conclusion. Use of TNF-alpha inhibitor was not associated with differences in lipid levels in patients with RA. (First Release April 1 2012; J Rheumatol 2012;39:946-8; doi:10.3899/jrheum.111093)
引用
收藏
页码：946 / 948
页数：3
相关论文
共 50 条
  • [31] Golimumab: A Tumor Necrosis Factor Alpha Inhibitor for the Treatment of Rheumatoid Arthritis
    McCluggage, Lauren K.
    Scholtz, Jean M.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (01) : 135 - 144
  • [32] Acquired Factor VIII Inhibitor in a Patient of Rheumatoid Arthritis on Tumor Necrosis Factor Inhibitor Therapy
    Mori, Tomoyo
    Watanabe, Naoki
    Kitahara, Hideaki
    Iwao, Noriaki
    Koike, Michiaki
    Komatsu, Norio
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2019, 35 (01) : 192 - 193
  • [33] Acquired Factor VIII Inhibitor in a Patient of Rheumatoid Arthritis on Tumor Necrosis Factor Inhibitor Therapy
    Tomoyo Mori
    Naoki Watanabe
    Hideaki Kitahara
    Noriaki Iwao
    Michiaki Koike
    Norio Komatsu
    Indian Journal of Hematology and Blood Transfusion, 2019, 35 : 192 - 193
  • [34] The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis
    Kavanaugh, A
    Cohen, S
    Cush, JJ
    JOURNAL OF RHEUMATOLOGY, 2004, 31 (10) : 1881 - 1884
  • [35] Rheumatoid arthritis and tumor necrosis factor α
    Abe, T
    Takeuchi, T
    AUTOIMMUNITY, 2001, 34 (04) : 291 - 303
  • [36] ULTRASONOGRAPHIC ASSESSMENT OF JOINT INFLAMMATION IN RHEUMATOID ARTHRITIS: PREDICTIVE VALUE IN RESPONSE TO TUMOR NECROSIS FACTOR-α INHIBITOR TREATMENT
    Inanc, N.
    Ozen, G.
    Direskeneli, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 468 - 468
  • [37] Tumor Necrosis Factor-α Inhibitor-induced Antiglomerular Basement Membrane Antibody Disease in a Patient with Rheumatoid Arthritis
    Nishimura, Keisuke
    Saegusa, Jun
    Kawano, Seij
    Morinobu, Akio
    JOURNAL OF RHEUMATOLOGY, 2012, 39 (09) : 1904 - 1906
  • [38] Tumor necrosis factor-α (TNF) production is associated with lower body cell mass in rheumatoid arthritis [RA].
    Walsmith, J
    Snydman, L
    Roubenoff, R
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S80 - S80
  • [39] Reduced Cardiovascular Risk with Use of Methotrexate and Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis.
    Bozaite-Gluosniene, Rasa
    Tang, Xiaoqin
    Kirchner, H. Lester
    Antohe, Jana L.
    Morris, Stephanie J.
    Wasko, Mary Chester
    Bili, Androniki
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S279 - S280
  • [40] Interleukin 1 or tumor necrosis factor-α:: Which is the real target in rheumatoid arthritis?
    Dayer, JM
    JOURNAL OF RHEUMATOLOGY, 2002, 29 : 10 - 15
12345